[go: up one dir, main page]

BR0309418A - pró-drogas ativadas por peptìdeos deformilase - Google Patents

pró-drogas ativadas por peptìdeos deformilase

Info

Publication number
BR0309418A
BR0309418A BRPI0309418-9A BR0309418A BR0309418A BR 0309418 A BR0309418 A BR 0309418A BR 0309418 A BR0309418 A BR 0309418A BR 0309418 A BR0309418 A BR 0309418A
Authority
BR
Brazil
Prior art keywords
activated
deformylase
peptide
microorganism
prodrugs
Prior art date
Application number
BRPI0309418-9A
Other languages
English (en)
Inventor
Maria V Sergeeva
Venkata Ramana Doppalapudi
Original Assignee
Celmed Oncology Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celmed Oncology Usa Inc filed Critical Celmed Oncology Usa Inc
Publication of BR0309418A publication Critical patent/BR0309418A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)

Abstract

"PRó-DROGAS ATIVADAS POR PEPTìDEO DEFORMILASE". A presente invenção refere-se a um método para inibir o crescimento de um microorganismo que expressa Peptídeo Deformilase contatando-se o microorganismo com uma quantidade eficaz do composto descrito aqui. Este método inibe o crescimento de microorganismo gram-positivo e gram-negativo, por exemplo, S. aureus, S. epidermidis, K. pneumoniae, E. aerogenes, e E. cloacae. Este método pode ser praticado in vitro, ex vivo e in vivo. é também fornecido um método para aliviar os sintomas de uma infecção por um microorganismo expressando Peptídeo Deformilase em um indivíduo administrando ou liberando para o indivíduo uma quantidade eficaz do composto acima descrito.
BRPI0309418-9A 2002-04-18 2003-04-17 pró-drogas ativadas por peptìdeos deformilase BR0309418A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37408902P 2002-04-18 2002-04-18
PCT/US2003/011981 WO2003088913A2 (en) 2002-04-18 2003-04-17 Peptide deformylase activated prodrugs

Publications (1)

Publication Number Publication Date
BR0309418A true BR0309418A (pt) 2007-03-06

Family

ID=29251135

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309418-9A BR0309418A (pt) 2002-04-18 2003-04-17 pró-drogas ativadas por peptìdeos deformilase

Country Status (10)

Country Link
US (1) US20050096254A1 (pt)
EP (1) EP1499318A4 (pt)
JP (1) JP2006507219A (pt)
CN (1) CN1662238A (pt)
AU (1) AU2003225047A1 (pt)
BR (1) BR0309418A (pt)
CA (1) CA2482029A1 (pt)
IL (1) IL164658A0 (pt)
MX (1) MXPA04010230A (pt)
WO (1) WO2003088913A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163923B2 (en) 2001-05-09 2007-01-16 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
US7001922B2 (en) 2002-11-14 2006-02-21 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
EP1845087A1 (en) 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
DK2473480T3 (en) 2009-09-01 2016-09-05 Fab Pharma Sas Novel antibacterial hydroxyphenylforbindelse
CN107699498B (zh) * 2017-10-04 2020-09-25 北京康缘益生生物科技有限公司 一种降解有机磷农药的复合微生物制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053638A (en) * 1970-05-06 1977-10-11 William Wrigley Jr. Company Anticaries confectioneries and oral health products
JPS5223001A (en) * 1975-08-14 1977-02-21 Ajinomoto Co Inc Process for elimination of formyl group
US4083974A (en) * 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
HU181013B (en) * 1980-01-25 1983-05-30 Gyogyszerkutato Intezet Process for preparing new enkephalin analogues
DE3005845A1 (de) * 1980-02-16 1981-09-03 Boehringer Mannheim Gmbh, 6800 Mannheim Aminosaeure- und peptidester von leuko-indoanilinen, verfahren zu deren herstellung sowie diese verbindungen enthaltende mittel zum nachweis proteolytischer enzyme
US4427660A (en) * 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US4415590A (en) * 1982-04-26 1983-11-15 Betamed Pharmaceuticals, Inc. Herpes treatment
US5350681A (en) * 1986-08-18 1994-09-27 The Coca-Cola Company Enzymatic membrane method for the synthesis and separation of peptides
US5274113A (en) * 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
ATE195933T1 (de) * 1994-03-10 2000-09-15 Searle & Co L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren
ZA962455B (en) * 1995-03-31 1996-10-02 B Eugene Guthery Fast acting and persistent topical antiseptic
US5842441A (en) * 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US6448058B1 (en) * 1997-09-12 2002-09-10 Versicor, Inc. Methods for solid phase synthesis of mercapto compounds and derivatives, combinatorial libraries thereof and compositions obtained thereby
US6159706A (en) * 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
JP2002500880A (ja) * 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド 酵素に触媒される治療剤
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
WO2002007780A2 (en) * 2000-07-20 2002-01-31 Newbiotics, Inc. Methods for identifying therapeutic targets
US7163923B2 (en) * 2001-05-09 2007-01-16 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs

Also Published As

Publication number Publication date
JP2006507219A (ja) 2006-03-02
EP1499318A4 (en) 2006-07-19
WO2003088913A8 (en) 2005-01-06
EP1499318A2 (en) 2005-01-26
WO2003088913A3 (en) 2004-04-01
CN1662238A (zh) 2005-08-31
MXPA04010230A (es) 2005-06-08
US20050096254A1 (en) 2005-05-05
WO2003088913A2 (en) 2003-10-30
CA2482029A1 (en) 2003-10-30
IL164658A0 (en) 2005-12-18
AU2003225047A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
Rubinstein et al. Vancomycin-resistant enterococci
BR0111980A (pt) Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0311323B8 (pt) composto inibidor de c-aril glicosídeo sglt2, composição farmacêutica e combinação
BRPI0606690A2 (pt) composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
EP4483952A3 (en) Compositions suitable for treating collagen-mediated diseases
BR0212374A (pt) Oxintomodulina para a prevenção ou para o tratamento do excesso de peso
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
DE69833377D1 (de) Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BR0316629A (pt) Uréias e carbamatos substituìdos
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR0210149A (pt) Pródrogas ativadas por deformilase de peptìdeo
BR0309418A (pt) pró-drogas ativadas por peptìdeos deformilase
US6063775A (en) Retardation of metalloproteinase incidental to HIV and/or AIDS
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
BR0317947A (pt) Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes
WO2006108681A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
BR0211121A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.